Neuroendocrine tumours and their microenvironment by de Hosson, Lotte D et al.
 
 
 University of Groningen
Neuroendocrine tumours and their microenvironment
de Hosson, Lotte D; Takkenkamp, Tim J; Kats-Ugurlu, Gursah; Bouma, Grietje; Bulthuis,






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
de Hosson, L. D., Takkenkamp, T. J., Kats-Ugurlu, G., Bouma, G., Bulthuis, M., de Vries, E. G. E., van
Faassen, M., Kema, I. P., & Walenkamp, A. M. E. (2020). Neuroendocrine tumours and their
microenvironment. Cancer Immunology Immunotherapy, 69(8), 1449-1459. https://doi.org/10.1007/s00262-
020-02556-1
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Vol.:(0123456789) 
Cancer Immunology, Immunotherapy 
https://doi.org/10.1007/s00262-020-02556-1
ORIGINAL ARTICLE
Neuroendocrine tumours and their microenvironment
Lotte D. de Hosson1 · Tim J. Takkenkamp1 · Gursah Kats‑Ugurlu2 · Grietje Bouma1 · Marian Bulthuis2 · 
Elisabeth G. E. de Vries1 · Martijn van Faassen3 · Ido P. Kema3 · Annemiek M. E. Walenkamp1
Received: 17 July 2019 / Accepted: 26 March 2020 
© The Author(s) 2020
Abstract
Tumours can escape the immune system by expressing programmed death-ligand-1 (PD-L1), which allows them to bind 
to PD-1 on T-cells and avoid recognition by the immune system. Regulatory T-cells (Tregs), indoleamine 2,3-dioxygenase 
(IDO) and tryptophan 2,3-dioxygenase (TDO) also play a role in immune suppression. Knowledge about the interaction of 
neuroendocrine tumours (NETs) with their immune microenvironment and the role of immunotherapy in patients with NET 
is scarce. Here, we investigated the immune microenvironment of serotonin-producing (SP) and non-serotonin-producing 
NETs (NSP-NETs). Tumours of 33 patients with SP-NET and 18 patients with NSP-NET were studied. Immunohistochemi-
cal analyses were performed for PD-L1, T-cells, IDO, TDO, mismatch repair proteins (MMRp) and activated fibroblasts. 
PD-L1 expression was seen in < 1% of tumour and T-cells. T-cells were present in 33% of NETs, varying between 1 and 
10% T-cells per high power field. IDO was expressed in tumour cells in 55% of SP-NETs and 22% of NSP-NETs (p = 0.039). 
TDO was expressed in stromal cells in 64% of SP-NETs and 13% of NSP-NETs (p = 0.001). No tumours had loss of MMRp. 
TDO-expressing stromal cells also strongly expressed α-SMA and were identified as cancer-associated fibroblasts (CAFs). 
Factors that are associated with a response to checkpoint inhibitor treatment were absent or only present to a limited extent 
in the tumour microenvironment of NETs. The expression of IDO and TDO in a substantial part of NETs and the presence of 
CAFs suggest two mechanisms that could be responsible for the cold immune microenvironment, which should be explored 
to enhance anti-tumour immunity and clinical responses.
Keywords Neuroendocrine tumours · Programmed death-ligand-1 · Indoleamine 2,3-dioxygenase · Tryptophan 
2,3-dioxygenase · T-cells · Immune microenvironment
Abbreviations
5-HIAA  5-Hydroxyindolacetic acid
α-SMA  α-Smooth muscle antigen
CAF  Cancer associated fibroblast
HE  Hematoxylin and eosin
HPLC  High-performance liquid chromatography
IDO  Indoleamine 2,3-dioxygenase
MMRp  Mismatch repair proteins
NEN  Neuroendocrine neoplasm
NET  Neuroendocrine tumour
NSP-NET  Non-serotonin-producing NET
PD-L1  Programmed death-ligand-1
PD-1  Programmed death-1
PFS  Progression-free survival
PRP  Platelet-rich plasma
SP-NET  Serotonin-producing NET
TGF-β  Transforming growth factor-beta
TDO  Tryptophan 2,3-dioxygenase
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Treg  Regulatory T-cell
VDS  Virtual double staining
Introduction
Neuroendocrine tumours (NETs) comprise a heterogeneous 
group of tumours that are predominantly derived from the 
enterochromaffin cells of the gastro-enteropancreatic tract or 
bronchopulmonary system [2]. NETs grade 1 and 2 can pro-
duce various biogenic amines and polypeptide hormones, of 
which serotonin is the most common [3]. Radical resection 
of the NET is the only curative possibility. However, NET 
patients often present with non-resectable or metastatic dis-
ease. Non-curative systemic treatment aimed at controlling 
symptoms and progression of disease includes somatostatin 
analogues, interferon, everolimus, sunitinib, peptide recep-
tor radionuclide therapy and chemotherapy [4]. None of the 
currently used systemic treatments for NET grade 1 and 2 
were rated as having substantial clinical benefit according to 
the ‘European Society of Medical Oncology magnitude of 
clinical benefit scale’ [5]. Consequently, there is an unmet 
need for new and better systemic treatment modalities.
In recent last years, immunotherapy with immune check-
point inhibiting antibodies has shown anti-tumour activity 
across numerous tumour types. These therapies target the 
cell surface proteins programmed death-ligand-1 (PD-L1) 
on tumour and immune/non-immune cells and programmed 
death-1 (PD-1) on monocytes/lymphocytes [6]. Targeting 
PD-L1 and PD-1 leads to activated T-cells in the tumour 
microenvironment. However, little research has been pub-
lished on the activity of these drugs in NETs.
Clinical studies have shown that a number of additional 
factors are associated with a response to checkpoint inhibitor 
treatment, such as the presence of T-cells and high muta-
tional tumour load [7]. In addition, major interest has been 
shown in the tryptophan-degrading enzymes indoleamine 
2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase 
(TDO). These enzymes convert tryptophan into kynurenine, 
along the kynurenine pathway, which could lead to deple-
tion of tryptophan in the tumour microenvironment [8–10]. 
Tryptophan is also the precursor of serotonin. IDO and TDO 
are especially of interest in NETs as these tumours often 
produce serotonin, which potentially depletes its precursor 
tryptophan [11].
Surprisingly little is currently known about the complex 
interactions of NET cells with their surrounding immune 
microenvironment. Studies examining T-cells in neuroen-
docrine neoplasms showed the presence of T-cells in most 
NETs, but the amount of T-cells varied and number of 
tumours with Tregs or FoxP3-positive cells varied between 
26 and 34% [12, 13]. Furthermore, limited PD-L1 expres-
sion in NET cells has been observed in six studies, while 
in two other studies more than half of NETs had PD-L1 
expression [14–16]. The use of different PD-L1 antibodies 
in the various studies may account for these heterogeneous 
findings.
We investigated the tumour immune microenvironment—
in particular the presence of PD-L1, T-cells, IDO, TDO, 
MMRp and cancer-associated fibroblasts (CAFs)—in tissue 
from patients with treatment-naive serotonin-producing (SP) 
and non-serotonin-producing NET (NSP-NET) grade 1 or 2 
in this exploratory study. Furthermore, we related the immu-
nohistochemical data to overall survival of the patients.
Material and methods
Participants
Medical records of newly referred NET patients to the 
Department of Medical Oncology of the University Medi-
cal Center Groningen (UMCG) between January 1, 2008, 
and December 31, 2014, were screened. Patients diagnosed 
with a NET grade 1 or 2 according to the World Health 
Organization 2010 classification were selected. A patient 
was diagnosed with a SP-NET when urinary 24-h excretion 
of 5-HIAA was > 3.8 mmol/mol creatinine and/or platelet 
serotonin > 5.4 nmol/109 platelets [10]. Serotonin produc-
tion and 5-hydroxyindolacetic acid (5-HIAA) in 24-h (24-h) 
urine were measured by high-performance liquid chroma-
tography (HPLC) [17].
We included NET patients with tumour tissue, platelet-
rich plasma (PRP) for analysis of serotonin and/or urinary 
24-h excretion of 5-hydroxyindolacetic acid (5-HIAA) avail-
able before start of systemic anti-tumour treatment. Somato-
statin analogue use was allowed for maximal 14 days before 
tumour tissue was collected. We excluded NET patients 
with other primary solid/haematological malignancy, auto-
immune disease (e.g. colitis) or infectious disease (e.g. hepa-
titis) as well as patients with concomitant use of treatment 
interfering with IDO activity (e.g. interferon).
Patients were clinically staged according to the Union for 
International Cancer Control guidelines [18]. Histopatholog-
ical analysis of the formalin-fixed paraffin-embedded tumour 
tissue of the patients was centrally reviewed by a dedicated 
NET pathologist (Gursah Kats-Ugurlu).
Tumour histology and Immunohistochemistry
In all tumour samples, 3-µm slides of formalin-fixed paraf-
fin-embedded tumour samples were studied for morphol-
ogy and mitotic count on standard hematoxylin and eosin 
(HE) stain, and proliferation index was determined using 
immunohistochemistry-based Ki-67 stain (mouse anti-Ki67, 
MiB-1 clone, dilution 1:100 Dako, Glostrup, Denmark). Two 
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antibodies for PD-L1 staining were used: mouse anti-PD-L1 
(clone 22C3, 1:50, Dako, Glostrup, Denmark) and rabbit 
anti-PD-L1 (clone E1L3N, 1:200 Cell Signaling Technol-
ogy, Danvers, MA, USA). PD-L1 antibodies were applied in 
the Ventana Ultra staining system. To detect MMR antigens, 
we used anti-MLH-1 mouse monoclonal primary antibody 
(clone M1, Roche Diagnostics, IN, USA), PMS2 rabbit 
monoclonal antibody (clone EPR3947, Cell Marque, CA, 
USA), MSH2 mouse monoclonal antibody (clone G219-
1129, Cell Marque) and CONFIRM anti-MSH6 mouse 
monoclonal primary antibody (clone 44, Roche Diagnos-
tics). The mouse anti-CD3 antibody (1:50, Monosan, San-
bio, Uden, the Netherlands) was used to recognise T-cells. 
Antibodies against IDO (mouse anti-IDO, MAB5412, 1:25, 
Chemicon, Millipore, Amsterdam, the Netherlands), TDO 
(rabbit anti-TDO2, clone HPA 039,611, 1:200, Atlas Anti-
bodies, Bromma, Sweden) desmin (M0760, dilution Dako 
1:50, Madrid, Spain) and α-SMA (mouse anti-SMA, clone 
1A4, 1:1000, Sigma, MI, USA) were applied. α-SMA and 
desmin are well-established markers for myofibroblasts and 
myofibroblast-like cells in the tumour microenvironment, 
also known as CAFs [19, 20].
One pathologist (Gursah Kats-Ugurlu) and two research-
ers (Grietje Bouma and Lotte D. de Hosson) evaluated the 
stained slides at a double-head microscope blinded for clini-
cal and histopathological information. To avoid a learning 
effect, every first 10 slides that were scored and slides that 
were difficult to score were scored again without knowledge 
of the first score. Positive external controls were placenta for 
PD-L1, appendix for the MMR antigens and CD3, lymph 
node for IDO and prostate for TDO. For α-SMA, the peri-
cytes of blood vessels served as internal control.
The tumour and its immediate environment were evalu-
ated. Tumour cells with ≥ 1% positive staining for PD-L1, 
IDO and TDO were defined as positive. MMRp loss was 
assumed if tumour cell nucleus showed no staining in com-
parison with internal inflammatory cells or appendix as 
external control. T-cells were scored ‘present’ if ≥ 1% of 
the cells in a high power field composed of T-cells distrib-
uted patchily or diffusely in CD3. PD-L1 showed a mem-
branous staining pattern of tumour cells, and IDO showed a 
cytoplasmic staining pattern with the presence of acellular 
small depositions. Besides a cytoplasmic staining pattern, 
TDO showed expression in tumour stroma. α-SMA staining 
was performed to further characterise TDO-positive stromal 
cells on five tumours with TDO expression in stroma and on 
five without TDO expression in stroma. Furthermore, stain-
ing with desmin, another marker for CAFs, was performed. 
Virtual double staining (VDS) (Visiopharm©) with HE and 
α-SMA showed the close vicinity of stroma cells that were 
identified as CAFs and tumour cells. Stained slides were 
scanned at an objective magnification of 40× using Philips 
Ultra Fast Scanner 1.6 and were saved in the image file for-
mat i-Syntax.
The method described below was used for the analysis of 
the slides. First, alignment on a large scale was performed 
on the images of adjacent slides stained for HE and α-SMA. 
Visiopharm presented the best possible match of the 2 tis-
sue sections on a finer detail level, which was verified by a 
technician. Thereafter, cells were identified by shape and 
size with a fully automated watershed-based segmentation 
technique to separate cells positive and negative for α-SMA 
from the background. Double staining for α-SMA and TDO 
was performed using an alkaline phosphatase-based blue 
chromogen for α-SMA and using nova-red chromogen for 
TDO. To determine which T-cell subsets were present, VDS 
was used for 3 tumours stained with CD3 and CD8 antibod-
ies (ready to use antibodies of Ventana BenchMark). The 
CD3-positive and CD8-positive cells were counted manually 
by the pathologist, and the CD8/CD3 ratio was calculated.
Overall survival
Overall survival data were obtained from patient records in 
December 2019.
Statistical analysis
For this exploratory study, no sample size calculation 
was performed. Descriptive statistics (e.g. median, ranges 
and frequencies) were calculated for all measures. The 
Mann–Whitney U test was used to compare distributions 
across groups. Associations of categorical variables were 
tested using the Chi-square test. Hazard ratios for relation 
between immunohistochemical data and overall survival 
were calculated with Cox regression analysis.
Tests were performed two-sided, and p values < 0.05 were 
considered significant. Analyses were executed using the 




Clinical and pathological characteristics at the time of 
tumour collection of all SP-NET (N = 33) and NSP-NET 
(N = 18) patients are summarised in Table 1. Thirteen SP-
NET patients were treated briefly with somatostatin ana-
logues before tissue sampling. The brief use of somatostatin 
analogues was unavoidable in 13 out of 51 (25%) patients, 
as this was prescribed to prevent a carcinoid crisis during 
an invasive procedure.
 Cancer Immunology, Immunotherapy
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Expression of PD‑L1, MMR, the presence 
of tumour‑infiltrating T‑cells, IDO and TDO in NETs
None of the tumours were positive for PD-L1 when stained 
with anti-22C3 or anti-E1L3N stains. None of the tumours 
showed loss of the MMRp, and T-cells were present in 15 of 
the 45 samples, varying between 1 and 10% T-cells per high 
power field (Table 2). T-cells were most frequently found 
within the stroma of NETs of the jejunum/ileum (in 7 of 22 
samples), which were all SP-NETs (Table 3). Of 3 tumours 
that presented T-cells, the CD8/CD3 ratio was 70/120, 6/25 
and 3/10, respectively (Fig. 1). Correlation between T cell 
infiltration versus MMRp, IDO, TDO could not be detected 
due to small numbers in the subgroups.
IDO expression was restricted to tumour cells and varied 
between focal and diffuse presence of intracytoplasmic acel-
lular small depositions. IDO expression in tumour cells was 
more frequently observed in SP-NETs (55%, 18/33) than in 
NSP-NETs (22%, 4/18) (p = 0.0039, Table 2).
Three distinct patterns of TDO expression were found in 
the NETs: in tumour cells, in stroma or in both (Fig. 2). NETs 
expressed TDO in either the tumour cells (37%, 17/46) or 
stroma (44%, 18/41) (Table 2). Remarkably, TDO in stroma 
was observed in 64% (16/25) of evaluable SP-NETs and 13% 
(2/16) of the NSP-NETs (p = 0.0001). To investigate the ori-
gin of these TDO-positive stromal cells, α-SMA staining was 
performed on 10 slides, which showed that these cells strongly 
expressed α-SMA and desmin and were spindle-shaped. This 
Table 1  Clinicopathological 
characteristics of patients
NET neuroendocrine tumour, NSP-NET non-serotonin-producing neuroendocrine tumour, SP-NET seroto-
nin-producing neuroendocrine tumour
a Values are reported as number (percentage) unless noted otherwise
b Other sites of the tissue sample collection were mesenterium of the small intestine (N = 2), colon (N = 1), 
stomach (N = 1), peritoneum (N = 1)
NET patients 
(N = 51) a
NSP NET (N = 18) SP NET (N = 33)
Mean age in years ± SD 62.8 ± 11.0
Male sex 30 (59) 11 (61) 19 (58)
Primary tumour location
Lung 2 (4) 2 (11) 0 (0)
Stomach 1 (2) 1 (6) 0 (0)
Duodenum 2 (4) 2 (11) 0 (0)
Pancreas 14 (27) 11 (61) 3 (9)
Jejunum/ileum 22 (43) 0 (0) 22 (67)
Colon/rectum 2 (4) 1 (6) 1 (3)
Unknown 8 (16) 1 (6) 7 (21)
Tumour grade
Grade 1 34 (67) 8 (44) 25 (76)
Grade 2 16 (31) 10 (56) 6 (18)
Unknown 1 (2) 0 (0) 2 (6)
Disease stage
Stage 1/2 3 (6) 2 (11) 1 (3)
Stage 3/4 46 (90) 15 (83) 31 (94)
Unknown 2 (4) 1 (6) 1 (3)
Source of tissue sample
Primary tumour 30 (59) 10 (56) 20 (61)
Metastasis 20 (39) 8 (44) 12 (36)
Unknown 1 (2) 0 (0) 1 (3)
Location of tissue sample
Liver 14 (27) 8 (44) 6 (18)
Lymph node 4 (8) 1 (6) 3 (9)
Jejunum/ileum 18 (35) 0 (0) 18 (55)
Pancreas 5 (10) 3 (17) 2 (6)
Duodenum 3 (6) 3 (17) 0 (0)
Lung 2 (4) 1 (6) 1 (3)
Otherb 5 (10) 2 (6) 3 (9)
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was confirmed with double staining of α-SMA and TDO 
(Fig. 3). Furthermore, these cells were located within the 
vicinity of tumour cells, as shown with VDS (Fig. 4). The 
stromal cells were therefore identified as CAFs [21–23].
Relation of immunohistochemical data and overall 
survival
Median follow-up was 63 months (range 1–162 months); 
26 patients died. No statistical significant differences in 
overall survival were seen in patients with the presence or 
absence of either CD3, IDO or TDO in tumour, nor for TDO 
in stroma (Supplementary data).
Discussion
Our exploration of the immune microenvironment of NETs 
revealed that tumour cells in NETs did not express PD-L1. In 
addition, only a minority of NETs contained a small number 
of T-cells. A substantial proportion of NETs expressed IDO 
and TDO, and TDO was also expressed by stromal cells. 
None of the tumours were MMRp-deficient. These cells 
were identified as CAFs due to the positive staining with 
α-SMA and desmin. Furthermore, VDS showed their close 
vicinity to tumour cells [19, 20].
Our study showed that NETs exhibit a ‘cold’ tumour 
microenvironment lacking several characteristics that have 
recently been associated with a response to checkpoint 
inhibitor treatment [6]. The expression of IDO and TDO in 
a substantial proportion of NETs and the presence of CAFs 
suggest that these two mechanisms could be responsible for 
the cold immune microenvironment.
Interestingly, an immunohistochemical analysis of lung 
cancer specimens revealed increased TDO2 expression 
in CAFs. Furthermore, administration of TDO2 inhibitor 
improved T-cell response and decreased tumour metastasis 
in mice with metastatic lung cancer [24]. The enzymes IDO 
and TDO degrade tryptophan into kynurenines, resulting 
in a tryptophan depleted tumour microenvironment rich of 
Table 2  The presence of 
T-cells, expression of IDO, 
TDO, PD-L1 and MMRp in 
NETs
IDO indoleamine 2,3-dioxygenase, MMRp mismatch repair proteins, NET neuroendocrine tumour, NSP-
NETs non-serotonin-producing neuroendocrine tumour, PD-L1 programmed death-ligand 1, SP-NETs sero-
tonin-producing neuroendocrine tumour, TDO tryptophan 2,3-dioxygenase
a Three tissue samples of SP-NETs with not evaluable stroma were TDO positive in the tumour
All NET N (%) NSP-NET N (%) SP-NET N (%) p-value
Tissue samples 51 (100) 18 (100) 33 (100)
PD-L1 expression (22C3 antigen)
Negative 51 (100) 18 (100) 33 (100) NS
Positive 0 (0) 0 (0) 0 (0)
PD-L1 expression ( E1L3N antigen)
Negative 51 (100) 18 (100) 33 (100) NS
Positive 0 (0) 0 (0) 0 (0)
MMRp
Loss of MMRp 0 (0) 0 (0) 0(0) NS
No loss of MMRp 51 (100) 18 (100) 33 (100)
T-cells
Absent 30 (59) 10 (56) 20 (61) NS
Present 15 (29) 6 (33) 9 (27)
Not evaluable 6 (12) 2 (11) 4 (12)
IDO expression
Negative 29 (57) 14 (78) 15 (45) 0.039
Positive 22 (43) 4 (22) 18 (55)
TDO expression in tumour cells
Negative 29 (63) 11 (65) 18 (62)a NS
Positive 17 (37) 6 (35) 11 (38)
Not evaluable 5 (10) 1 (6) 4 (12)
TDO expression in stroma
Negative 23 (56) 14 (88) 9 (36) 0.001
Positive 18 (44) 2 (13) 16 (64)
Not evaluable 10 (20) 2 (11) 8 (24)
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kynurenines. This microenvironment leads to suppression of 
effector T-cells or the conversion to tumour tolerant regula-
tory T-cells (Tregs) [8–10]. A number of IDO and TDO 
inhibitors have advanced into clinical trials with or without 
PD-1 antibody inhibitors in patients with solid tumours. 
Also an IDO1/TDO dual inhibitor is currently being tested in 
a phase I study [25, 26]. In the ECHO-301/KEYNOTE 252 
study, patients with unresectable or metastatic melanoma 
were randomised to receive pembrolizumab in combina-
tion with either epacadostat (an IDO-inhibitor) or placebo. 
Unfortunately, this phase III study was recently terminated 
early due to failure to improve progression-free survival 
(PFS) [27].
Preclinical studies have also suggested that aryl hydro-
carbon receptor could become another possible target of 
the IDO/TDO kynurenine pathway in the treatment of can-
cer, due to its immunosuppressive role in tumours [28]. 
Our data showed that especially serotonin-producing NET 
tumours express IDO and TDO. These patients often have 
low tryptophan levels, as tryptophan is the sole precursor of 
peripherally and centrally produced serotonin. This suggests 
that IDO-mediated immune suppression is most prominent 
Table 3  The presence of T-cells 
and immunohistochemical 
expression of IDO, TDO and 
PD-L1 classified by primary 
origin of the NET
IDO indoleamine 2,3-dioxygenase, MMRp mismatch repair proteins, NET neuroendocrine tumour, PD-L1 
programmed death-ligand 1, TDO tryptophan 2,3-dioxygenase




Pancreas N Lung N Unknown N Other Na
Tissue samples 22 14 2 8 5
T-cells
Absent 13 11 0 5 1
Present 7 1 1 3 3
Not evaluable 2 2 1 0 1
IDO expression
Negative 9 9 2 6 3
Positive 13 5 0 2 2
TDO expression in tumour cells
Negative 15 6 2 3 3
Positive 4 6 0 5 2
Not evaluable 3 2 0 0 0
TDO expression in stroma
Negative 2 12 1 5 3
Positive 15 1 0 1 1
Not evaluable 5 1 1 2 1
PD-L1 expression 0 0 0 0 0
MMRp 0 0 0 0 0
Fig. 1  The presence of CD3 and CD8 expressing T-cells in a sero-
tonin-producing NET of the ileum. CD3 and CD8 expressing T-cells 
in a serotonin-producing ileum resection specimen. a CD3 expression 
(200×), b CD8 expression (200×). Cells presenting both CD3 and 
CD8 (black arrows) and other cells that are only CD3 positive (grey 
arrows)
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Fig. 2  Expression of IDO, TDO and α-SMA and IDO in a seroto-
nin-producing NET of the ileum. Illustrative images of indoleam-
ine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) 
expression in a serotonin-producing neuroendocrine tumour (NET) in 
ileum resection specimen. (a HE, 20×). Magnification of the submu-
cosal NET (b HE, 200×). At lower magnification, IDO is not detect-
able (c, IDO, 20×) In higher magnification, a diffuse, strong brown 
intracytoplasmic, dot-like IDO expression (marked by arrows) is seen 
in tumour cells (d IDO, 1000×). TDO expression is visible in stro-
mal cells surrounding the tumour cells (e TDO, 20× , f TDO, 200×). 
α-SMA is expressed in stromal cells (grey arrows) between tumour 
cells (black arrows) and has a stronger expression in areas with more 
TDO expression (g α-SMA, 20×, h α-SMA, 200×)
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in patients with low tryptophan levels, and these patients 
might therefore be interesting candidates for treatment with 
immune checkpoint inhibitors combined with IDO inhibi-
tors. In our study, however, we did not find an association 
between IDO expression and the presence of T-cells, which 
might be an indication of the complex interaction of tumours 
and their immune microenvironment.
Preclinical studies in mouse models of various cancer 
types showed that CAFs, together with other stromal cells, 
are responsible for restricting the accumulation of T-cells in 
the vicinity of cancer cells [29]. Furthermore, CAFs act by 
secreting various growth factors such as transforming growth 
factor-beta (TGF-β) [22, 30]. Increased TGF-β in the tumour 
immune microenvironment was recently shown to represent 
a primary mechanism of immune evasion that promotes 
T-cell exclusion [31]. In patients with metastatic urothelial 
carcinoma, lack of response to immune checkpoint blockade 
is associated with increased TGF-β signalling in fibroblasts 
in the tumour microenvironment [31]. Combining TGF-β 
blockade with immune checkpoint blockade in mouse mod-
els increases the anti-tumour efficacy of the therapy, sug-
gesting that identifying and targeting microenvironmental 
regulators of anti-tumour immunity may increase the reach 
of immunotherapeutical approaches [32].
Therefore, we used two validated PD-L1 antibodies—
22C3 and E1L3N—which both showed no expression of 
PD-L1 in NET cells.
In contrast to NETs, grade 3 neuroendocrine neoplasms 
(NENs) were characterised by strong PD-L1 expression [33]. 
A correlation between tumour grade and PD-L1 expression 
was also seen in neuroendocrine neoplasms of pulmonary 
origin [15, 34]. One study involving 32 patients treated with 
systemic therapy for gastro-intestinal and pancreatic NENs 
found that PD-L1 expression was associated with PFS [35]. 
Furthermore, a multivariate analysis of 80 pulmonary NENs 
revealed that PD-L1 expression, PD1 expression and distant 
metastasis of pulmonary NENs were independently associ-
ated with survival time [15].
In the current study, we observed a paucity of T-cells with 
fewer CD8-positive cells, in line with several other studies 
analysing NET immunohistochemically [36]. In one study, 
samples from 31 midgut NETs (grade 1 and 2) were ana-
lysed. Overall, the tumours contained a higher proportion 
of Tregs compared with matched normal tissue [36]. Other 
Fig. 3  Double staining in a 
serotonin-producing NET of the 
ileum. Illustrative image of dou-
ble staining with α-SMA and 
TDO expression in a serotonin-
producing ileum resection spec-
imen. a HE staining (50×), b 
α-SMA in alkaline phosphatase 
(blue) and TDO expression in 
nova-red (red) (50×). Purple 
colour shows stromal cells with 
expression of α-SMA and TDO 
(black arrows), and others only 
express α-SMA (grey arrows)
Fig. 4  Expression of α-SMA and desmin in a serotonin-producing NET of the ileum. Illustrative images of α-SMA and desmin expression in a 
serotonin-producing ileum resection specimen. a (HE 400×), b (α-SMA 400×), c (desmin 400×)
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studies examining T-cells in neuroendocrine neoplasms 
reported more CD3 expressing T-cells. In one of these stud-
ies, 68% of pancreatic NETs (N = 87) and 97% of NET liver 
metastases of patients (N = 39) with various primary tumour 
sites contained > 10 intratumoural T-cells per 10 high power 
fields. Tregs were found in 34% of pancreatic NETs and 
33% of NET liver metastases [12]. Other studies reported 
found tumour-infiltrating lymphocytes (TILs) in 14 out of 
17 samples, varying from single positive cells to multiple 
positive cells [13].
In our study, the paucity of T-cells in NETs and the rela-
tively high rate of Tregs might be the result of CAFs and 
their secreted factors and of IDO and TDO expression in the 
tumour and microenvironmental cells. In other tumour types, 
such as colorectal, oesophageal and endometrial cancer, an 
inverse correlation between IDO expression and T-cells has 
been observed [37]. We could not demonstrate a difference 
in the presence of T-cells in SP-NET and NSP-NET samples 
although serotonin is considered a pro-inflammatory modu-
lator that promotes invasion of neutrophils and other cells 
in acute inflammation. Further studies in larger sample sizes 
are therefore needed [38, 39].
The PD-1 antibodies pembrolizumab and nivolumab 
are registered for the treatment of several tumour types. 
Furthermore, nivolumab is registered for MMRp-deficient 
metastatic colorectal cancer and pembrolizumab for MMRp-
deficient tumours, irrespective of the primary tumour [7]. 
In MMRp-proficient tumours, probable DNA base pairing 
errors are corrected in newly replicated DNA, leading to 
microsatellite stable tumours. The equivalence of micros-
atellite instability testing and MMR immunohistochemistry 
was shown in endometrium carcinoma [40]. The validity 
of immunohistochemistry for MMRp to identify patients 
with microsatellite instable cancer has also been shown for 
colorectal cancer [41]. In our study, all investigated NETs 
were MMRp-proficient. This is in line with a study of 35 
pancreatic NETs and 34 small intestinal NETs in which all 
pNETs and 31 small intestinal NETs were MMRp-proficient, 
and with another study in which all included 70 pancreatic 
NETs were microsatellite-stable [14].
Little data have been published on treatment with immune 
checkpoint inhibition in NET patients. In the multicohort 
phase 1B KEYNOTE-028 study, 41 pre-treated patients 
with pancreas, lung and gut NET were treated with pem-
brolizumab. Results showed four patients with objective 
response and 29 patients with stable disease. Eight patients 
had severe (grade ≥ 3) treatment-related adverse events [42]. 
In the phase 2 KEYNOTE-158 study, 107 patients with well-
differentiated and moderately differentiated NETs of several 
primary sites were treated with pembrolizumab [43]. Four 
patients had a partial response, all patients with a PD-L1 
negative tumour. Sixty-one patients had stable disease, and 
the remaining had progressive disease. In a phase II trial, 
33 patients with low-grade, intermediate-grade and high-
grade NETs were treated with a dual checkpoint blockade 
nivolumab and ipilimumab. Partial or complete responses 
were seen only in patients with high-grade NETs: overall 
response rate of this group was 44% [44]. An explanation for 
the better response in high-grade NETs may be the presence 
of a higher tumour mutational burden.
Multiple phase 1 and 2 trials are currently recruiting NET 
patients for immune checkpoint inhibitor treatment [45].
Our findings indicate that both tumour and CAFs express 
IDO and TDO in NET patients. We therefore hypothesise 
that NET patients will potentially benefit from combina-
tion immunotherapies to overcome this cold immune micro-
environment. Further studies could elucidate the complex 
immune microenvironment of NETs.
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